United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir 250 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection. coadministration of viracept is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in table 3 ]. coadministration of viracept is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in table 3 [also see drug interactions (7), table 6 ]. pregnancy category b viracept should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there are no adequate and well-controlled studies in pregnant women taki

United States - English - NLM (National Library of Medicine)

agouron - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir 250 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection. coadministration of viracept is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in table 3 [also see drug interactions (7), table 6 ]. alpha 1-adrenoreceptor antagonist alfuzosin potentially increased alfuzosin concentrations can result in hypotension. antiarrhythmics amiodarone, quinidine potential for serious and/or life-threatening cardiac arrhythmia. antimycobacterial agents rifampin plasma concentrations of nelfinavir can be reduced by concomitant use of rifampin. this may lead to loss of therapeutic effect and possible development of resistance to viracept or other coadministered antiretroviral agents. antipsychotics ergot derivatives dihydroergotamine, ergotamin

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir mesylate 625 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv infection. in the clinical studies described below, efficacy was evaluated by the percent of patients with plasma hiv rna < 400 copies/ml (studies 511 and 542) or < 500 copies/ml (study actg 364), using the roche rt-pcr (amplicor) hiv-1 monitor or < 50 copies/ml, using the roche hiv-1 ultrasensitive assay (study avanti 3). in the analysis presented in each figure, patients who terminated the study early for any reason, switched therapy due to inadequate efficacy or who had a missing hiv-rna measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have hiv-rna above 400 copies/ml, above 500 copies/ml, or above 50 copies/ml at subsequent time points, depending on the assay that was used. study 511 was a double-blind, randomized, placebo controlled trial comparing treatment with zidovudine (zdv; 200 mg tid) and lamivudine (3tc; 150 mg bid) plus 2 doses

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir 250 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv infection. in the clinical studies described below, efficacy was evaluated by the percent of patients with plasma hiv rna < 400 copies/ml (studies 511 and 542) or < 500 copies/ml (study actg 364), using the roche rt-pcr (amplicor) hiv-1 monitor or < 50 copies/ml, using the roche hiv-1 ultrasensitive assay (study avanti 3). in the analysis presented in each figure, patients who terminated the study early for any reason, switched therapy due to inadequate efficacy or who had a missing hiv-rna measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have hiv-rna above 400 copies/ml, above 500 copies/ml, or above 50 copies/ml at subsequent time points, depending on the assay that was used. study 511 was a double-blind, randomized, placebo-controlled trial comparing treatment with zidovudine (zdv; 200 mg tid) and lamivudine (3tc; 150 mg bid) plus 2 doses

Canada - English - Health Canada

pfizer canada ulc - nelfinavir (nelfinavir mesylate) - tablet - 250mg - nelfinavir (nelfinavir mesylate) 250mg - hiv protease inhibitors

Canada - English - Health Canada

pfizer canada ulc - nelfinavir (nelfinavir mesylate) - powder - 50mg - nelfinavir (nelfinavir mesylate) 50mg - hiv protease inhibitors

Canada - English - Health Canada

pfizer canada ulc - nelfinavir (nelfinavir mesylate) - tablet - 625mg - nelfinavir (nelfinavir mesylate) 625mg - hiv protease inhibitors

Namibia - English - Namibia Medicines Regulatory Council

cipla medpro (pty) ltd - nelfinavir mesylate - tablet - each tablet contains: nelfinavir mesylate equivalent to nelfinavir 250,0mg

United States - English - NLM (National Library of Medicine)

padagis us llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 1 mg in 1 ml - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore, contraindicated (see warnings, cyp3a4 inhibitors ). dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 4 mg in 1 ml - dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings, cyp 3a4 inhibitors ). dihydroergotamine mesylate nasal spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms